Background Recent studies have provided a detailed census of genes that are mutated in
acute myeloid leukemia (AML). Our next challenge is to understand how this genetic diversity …

Background Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor
outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin — an …

Background Mutations occur in several genes in cytogenetically normal acute myeloid
leukemia (AML) cells: the nucleophosmin gene (NPM1), the fms-related tyrosine kinase 3 gene (…

Background All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for
acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of …

Context The optimal treatment of acute myeloid leukemia (AML) in first complete remission (CR1)
is uncertain. Current consensus, based on cytogenetic risk, recommends …

Background In patients with acute myeloid leukemia (AML), the presence or absence of
recurrent cytogenetic aberrations is used to identify the appropriate therapy. However, the …

To assess the prognostic relevance of activating mutations of theFLT3 gene in homogeneously
treated adults 16 to 60 years of age with acute myeloid leukemia (AML) and normal …

To assess the prognostic relevance of mutations in the NPM1 gene encoding a nucleocytoplasmic
shuttle protein in younger adults with acute myeloid leukemia (AML) and normal …

… Provision of study materials or patients: Richard F. Schlenk, Katharina … Schlenk RF,
Döhner K, Pralle H, et al: Riskadapted therapy in younger adults with acute myeloid …

Conventional cytogenetic analysis in B-cell chronic lymphocytic leukemia (B-CLL) has been
very difficult, and the prognostic significance of specific chromosome aberrations is under …